Incidence of CMV Infection and CMV Disease
| . | . | Antigenemia . | Culture . | CMV Disease . | Deaths . |
|---|---|---|---|---|---|
| CD34-selected PBSC | |||||
| Screening* | 19 | 5 (26.3%) | 1 (5.3%) | 3 (15.8%) | 1 (5.3%) |
| No screening | 12 | 4 (33.3%) | 3 (25%) | ||
| Total | 31 | 7 (22.6%) | 4 (12.9%) | ||
| Unselected PBSC | |||||
| Screening* | 172 | 30 (17.4%) | 4 (2.3%) | 5 (2.9%) | 3 (1.7%) |
| No screening | 65 | 5 (7.7%) | 2 (3.1%) | ||
| Total | 237 | 10 (4.2%) | 5 (2.1%) |
| . | . | Antigenemia . | Culture . | CMV Disease . | Deaths . |
|---|---|---|---|---|---|
| CD34-selected PBSC | |||||
| Screening* | 19 | 5 (26.3%) | 1 (5.3%) | 3 (15.8%) | 1 (5.3%) |
| No screening | 12 | 4 (33.3%) | 3 (25%) | ||
| Total | 31 | 7 (22.6%) | 4 (12.9%) | ||
| Unselected PBSC | |||||
| Screening* | 172 | 30 (17.4%) | 4 (2.3%) | 5 (2.9%) | 3 (1.7%) |
| No screening | 65 | 5 (7.7%) | 2 (3.1%) | ||
| Total | 237 | 10 (4.2%) | 5 (2.1%) |
Weekly CMV screening.